Luke Evnin Sells 107,429 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 107,429 shares of Werewolf Therapeutics stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $0.31, for a total value of $33,302.99. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Monday, July 6th, Luke Evnin sold 35,770 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.32, for a total value of $11,446.40.
• On Tuesday, June 9th, Luke Evnin sold 76,928 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total value of $28,463.36.
• On Monday, June 8th, Luke Evnin sold 60,547 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total value of $24,218.80.
• On Friday, June 5th, Luke Evnin sold 24,946 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total value of $9,978.40.
• On Thursday, June 4th, Luke Evnin sold 20,072 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.44, for a total value of $8,831.68.
• On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.42, for a total transaction of $12,494.58.
• On Tuesday, June 2nd, Luke Evnin sold 29,595 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $13,317.75.
• On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total transaction of $37,815.73.
• On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $14,650.20.
• On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.46, for a total transaction of $12,741.08.

Werewolf Therapeutics Price Performance

HOWL stock opened at $0.38 on Friday. The firm has a 50 day simple moving average of $0.44 and a two-hundred day simple moving average of $0.63. The stock has a market cap of $18.40 million, a PE ratio of -0.31 and a beta of 0.30. Werewolf Therapeutics, Inc. has a one year low of $0.27 and a one year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. On average, research analysts expect that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Qube Research & Technologies Ltd bought a new position in Werewolf Therapeutics during the 2nd quarter worth approximately $48,000. Regal Investment Advisors LLC lifted its position in Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after purchasing an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. lifted its position in Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after purchasing an additional 24,003 shares during the last quarter. AQR Capital Management LLC purchased a new stake in shares of Werewolf Therapeutics during the first quarter valued at approximately $79,000. Finally, Susquehanna International Group LLP boosted its stake in shares of Werewolf Therapeutics by 16.9% during the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after purchasing an additional 13,439 shares during the period. Institutional investors own 64.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on HOWL shares. Weiss Ratings lowered Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 16th. Wall Street Zen lowered Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.